Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 687 across all filing types
Latest filing 2021-10-07 Regulatory Filings
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Trading halt 2 pages 715.9KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX regarding a trading halt for Recce Pharmaceuticals Ltd. It does not contain financial data, report content, or detailed information about company performance or governance. It is a regulatory announcement about trading status, not a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-10-07 English
Court application and delayed cleansing notice 2 pages 247.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 8 October 2021 from Recce Pharmaceuticals Limited. It discusses a court application for an extension of time to lodge a cleansing notice related to the issue of shares on 2 September 2021. The document includes a notice pursuant to section 708A(5)(e) of the Corporations Act regarding the issue of shares without disclosure and compliance with relevant provisions. The content is primarily an announcement about a regulatory compliance matter and a court application, not a financial report or detailed financial data. The document length is 3744 characters, which is relatively short and consistent with an announcement rather than a full report. There is no financial data or detailed analysis present. Therefore, this document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-10-07 English
Application for quotation of securities - RCE 6 pages 27.7KB
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Recce Pharmaceuticals Ltd regarding the quotation of securities resulting from options being exercised or convertible securities being converted. It details the number and type of securities to be quoted, issue dates, and other related information. The content focuses on the issuance and quotation of shares following conversion of options, which aligns with announcements about share issues or capital changes. There is no indication of financial statements, management discussion, or regulatory certifications. The document is not a full financial report but an official announcement of a capital change event. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and detail support this classification with high confidence.
2021-10-07 English
R327 Phase I Clinical Trial Registered on ANZCTR 2 pages 297.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement regarding the registration of a clinical trial for Recce Pharmaceuticals' lead compound RECCE 327. It discusses the trial registration details, the nature of the trial, and some background on the company and its drug pipeline. There is no financial data, no mention of financial results, no regulatory filings related to financial statements, no management or board changes, no voting results, no capital or financing updates, and no legal proceedings. The document is a corporate announcement about a clinical trial registration, which is a regulatory announcement but does not fit into any of the more specific financial or governance categories. It is not a report or a presentation but an announcement of a significant corporate event related to clinical trials. Given the options, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2021-09-29 English
Appendix 4E 2 pages 271.7KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary Final Report for the financial year ended 30 June 2021' and contains detailed financial results for the full year ending 30 June 2021, including revenue, net loss, operational highlights, and financial commentary. It includes a comparison to the previous year, detailed operational and financial information, and dividend information. The document length is 3735 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Appendix 4E is a common Australian Securities Exchange (ASX) form used for preliminary final reports, which are equivalent to annual reports or full-year financial results. Therefore, this document is a full annual financial report rather than a brief announcement or a certification. It fits best under the Annual Report (10-K) category, which covers official yearly reports with full financial performance and company activity.
2021-08-30 English
Annual Report to shareholders 76 pages 5.9MB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2021' and contains detailed sections including Highlights, Message from the Chairman, Overview of Company Activities, Board of Directors & Key Management Personnel, Clinical and Regulatory updates, and a Financial Report section. The content includes comprehensive information about company activities, clinical trials, financial stability, management changes, and regulatory milestones. The length is substantial (15,000 characters), indicating a full report rather than a brief announcement. The presence of a financial report section and detailed company overview aligns with the characteristics of an Annual Report (10-K). There is no indication that this is merely an announcement of a report or a certification document. Therefore, the document is best classified as an Annual Report (10-K).
2021-08-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.